



**EISAI TO PROVIDE DIETHYLCARBAMAZINE CITRATE TABLETS  
FREE OF CHARGE FOR USE IN  
NATIONAL LYMPHATIC FILARIASIS ELIMINATION CAMPAIGN IN INDONESIA**

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has provided 151 million 100 mg tablets of the lymphatic filariasis treatment diethylcarbamazine citrate (DEC) free of charge for use in mass drug administration (MDA) conducted through the BELKAGA (Bulan Eliminasi Kaki Gajah: Lymphatic Filariasis Elimination Month) campaign being promoted by the Government of Indonesia.

Lymphatic filariasis, commonly known as elephantiasis, is a parasitic disease that is transmitted to humans by the bite of a mosquito. Once transmitted, it can cause lymphatic dysfunction which leads to pain as well as serious physical damage of disfigurement to parts of the body associated with lymphedema and other edemas. Currently, an estimated 120 million people are already affected and more than 1.3 billion people worldwide are at risk of this disease. There are over 100 million people at risk of infection in Indonesia alone, which makes Indonesia the region with the second biggest population at risk after India.

The Government of Indonesia views the elimination of lymphatic filariasis as an important policy issue, and in order to achieve elimination of (WHO). At an event to mark the beginning of BELKAGA held on October 1 in Bogor, West Java, Indonesia, Eisai conducted a mass drug administration (MDA) for 38,428 people.

**[Notes to editors]**

**1. About BELKAGA (Bulan Eliminasi Kaki Gajah: Lymphatic Filariasis Elimination Month)**

In Indonesia, many areas are endemic to lymphatic filariasis, and with approximately 40% of the population of over 100 million people at risk of infection, national-level